

QIBA Process Committee Meeting

Tuesday, May 2, 2023, at 2 pm (CT)

Meeting Summary

Attendees:

Kevin O'Donnell, MASC (Chair)

Michael Boss, PhD (Vice Chair)

Timothy Hall, PhD

Nancy Obuchowski, PhD

Nicholas Petrick, PhD

Daniel Sullivan, MD

RSNA Staff:

Susan Stanfa

Next Steps / Action Items:

Simplifying the QIBA Language for Ease of Use/Profile Template Updates

- Use of the word, “actor” to be avoided throughout
- Section 1: Executive Summary, Clinical Context, and Claims
 - Inclusion of history, i.e., clinical developments over the last years or decades and their basis, should be included in Appendix B
 - Clinicians and clinical trialists may not be familiar with repeatability Claims and/or the term, “confidence interval”; concise clarification to be added
- Section 3: Checklists
 - Requirement criteria, e.g., items with discernable impact on the performance of the biomarker, etc. to be added
 - Mr. O'Donnell to look into ways of facilitating the automatic conversion of checklists to an online form
- Section 4: Assessment Procedures
 - Profile writers should be clear re: what the procedure is going to do
 - Necessary specification for critical details should be included, leaving room for some flexibility, e.g., phantom to use, etc., and for international application
- A.2: Staff Qualification: requiring an explanation of how each requirement meets the three criteria (as needed) to be considered
- BCs to be encouraged to incorporate these updates into their Profiles

Process Committee Report for May 9th Steering Committee Meeting

- Mr. O'Donnell and Dr. Boss to develop presentation slides recommending QIBA practices
- Discussion needed BC/Profile sunseting process; overlap with the five-year review/update process for all QIBA Profiles is anticipated

Next Process Cmte Meeting on Tuesday, May 16, 2023, at 2 p.m. CT

- Review of Stage 4 requirements to resume